Roche (OTCMKTS:RHHBY) Reaches New 1-Year High – Here’s What Happened

Roche Holding AG (OTCMKTS:RHHBY)’s stock price hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $45.08 and last traded at $44.83, with a volume of 2653804 shares changing hands. The stock had previously closed at $41.81.

Roche Price Performance

The stock has a fifty day moving average price of $40.61 and a 200-day moving average price of $40.26.

Institutional Trading of Roche

A number of institutional investors have recently made changes to their positions in RHHBY. GAMMA Investing LLC boosted its position in shares of Roche by 6,463.8% in the 1st quarter. GAMMA Investing LLC now owns 528,778 shares of the company’s stock worth $21,759,000 after purchasing an additional 520,722 shares in the last quarter. Rhumbline Advisers boosted its position in shares of Roche by 7.4% in the 1st quarter. Rhumbline Advisers now owns 107,252 shares of the company’s stock worth $4,413,000 after purchasing an additional 7,374 shares in the last quarter. Fulton Bank N.A. boosted its position in shares of Roche by 2.6% in the 1st quarter. Fulton Bank N.A. now owns 12,620 shares of the company’s stock worth $518,000 after purchasing an additional 314 shares in the last quarter. Bard Financial Services Inc. boosted its position in shares of Roche by 25.3% in the 1st quarter. Bard Financial Services Inc. now owns 138,900 shares of the company’s stock worth $5,716,000 after purchasing an additional 28,050 shares in the last quarter. Finally, Riverbridge Partners LLC boosted its position in shares of Roche by 6.7% in the 1st quarter. Riverbridge Partners LLC now owns 37,826 shares of the company’s stock worth $1,557,000 after purchasing an additional 2,381 shares in the last quarter.

About Roche

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.